9)
risk of symtom reduction =85/210 =0.40
option E is correct
10)
std error =Se | =√(p*(1-p)/n) = | 0.0338 | ||
for 95 % CI value of z= | 1.960 | |||
margin of error E=z*std error = | 0.066 | |||
lower confidence bound=sample proportion-margin of error | 0.334 | |||
Upper confidence bound=sample proportion+margin of error | 0.466 |
option A is correct
8. There is a statistically significant difference in height between twin boys and girls. True or...
True or False? A clinical trial is conducted to compare an experimental medication to placebo to reduce the symptoms of asthma. Two hundred participants are enrolled in the study and randomized to receive either the experimental medication or placebo. The primary outcome is self-reported reduction of symptoms. Among 50 participants who receive the experimental medication, 30 report a reduction of symptoms as compared to 15 participants of 50 assigned to the placebo. The 95% CI for the relative risk of...
Question 21 1 pt A clinical trial is conducted to compare an experimental medication to placebo to reduce the symptoms of asthma. Participants are randomized to receive either the experimental medication or placebo. The primary outcome is self-reported reduction of symptoms. Among 140 participants who received the experimental medication, 85 reported a reduction of symptoms as compared to 47 participants of 140 assigned to placebo we need to generate a 95% cont dence inter al for the diference in proportions...
A clinical trial is conducted to compare an experimental medication to placebo to reduce the symptoms of asthma. Two hundred participants are enrolled in the study and randomized to receive either the experimental medication or placebo. The primary outcome is self-reported reduction of symptoms. Among 100 participants who receive the experimental medication, 38 report a reduction of symptoms as compared to 21 participants of 100 assigned to placebo. When you test if there is a significant difference in the proportions...
please provide a summary with intext citaion for this article: T HE HEART AND ESTROGEN/ progestin Replacement Study (HERS) was a randomized, blinded, placebo-controlled trial of the effect of 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate daily on coronary heart disease (CHD) event risk among 2763 postmenopausal women with documented CHD.1 Overall, during 4.1 years of follow-up, there were no significant differences between the hormone and placebo groups in the primary outcome of CHD events (nonfatal...